SAKAR HEALTHCARE
|
|
BOM :      NSE : SAKAR     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Dec 13,2024 |
Price(EOD): ₹ 319.15
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 692.56 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
SAKAR HEALTHCARE | -3.7% | 2.4% | -15.4% |
SUN PHARMACEUTICAL INDUSTRIES | 0.4% | 0.8% | 45.4% |
CIPLA | -1.5% | -5.1% | 20.3% |
DR REDDYS LABORATORIES | -0.7% | -1.3% | 13.8% |
ZYDUS LIFESCIENCES | -0.5% | 3% | 54.1% |
DIVIS LABORATORIES | -1.4% | 1.2% | 62% |
MANKIND PHARMA | 0% | 0.5% | 38.1% |
TORRENT PHARMACEUTICALS | 0.4% | 6.3% | 60.1% |
LUPIN | -1.5% | -0.6% | 72.3% |
FUNDAMENTAL ANALYSIS OF SAKAR HEALTHCARE
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SAKAR HEALTHCARE
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
55.97
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 12.40 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] 2.7
P/B Calculated based on Book Value of Rs 257.53 Cr
[Latest Year - Mar2024 - Consolidated Results ] 4.23
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 164.21 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
468% 324% 192% |
SHARE PRICE MOMENTUM OF SAKAR HEALTHCARE
SAKAR HEALTHCARE vs SENSEX
DEBT OF SAKAR HEALTHCARE
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.31 0.69 0.73 0.58 |
0.31 0.69 0.73 0.58 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF SAKAR HEALTHCARE
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF SAKAR HEALTHCARE
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
3.96% 7.5% 8.68% 98.84% |
25.53% 22.87% 23.16% 31.94% |
QtrlyTrend |
8 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
SAKAR HEALTHCARE related INDICES
You may also like the below Video Courses
FAQ about SAKAR HEALTHCARE
Is SAKAR HEALTHCARE good for long term investment?
As on Dec 13,2024, the Fundamentals of SAKAR HEALTHCARE look Strong and hence it may be good for long term investment! See Financial Performance of SAKAR HEALTHCARE . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SAKAR HEALTHCARE UnderValued or OverValued?
As on Dec 13,2024, SAKAR HEALTHCARE is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of SAKAR HEALTHCARE ?
As on Dec 13,2024, the Intrinsic Value of SAKAR HEALTHCARE is Rs. 75.36 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 56.14
Fair Value [Median EV / Sales Model] : Rs. 75.36
Fair Value [Median Price / Sales Model] : Rs. 109.43
Estimated Median Fair Value of SAKAR HEALTHCARE : Rs. 75.36
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.